Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Study of Tolerance Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Next Previous
Trial Profile

A Prospective Study of Tolerance Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netupitant/palonosetron (Primary) ; Cisplatin; Gemcitabine
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use

Most Recent Events

  • 02 Aug 2022 Akynzeo is an anti sickness drug, its not treating cancer. Hence Chemotherapy-induced-nausea-and-vomiting added as an indication As per treatment, Akynzeo is administered as an oral drug. Hence route and form can be assumed from RDI. Gemcitabine and cisplatin are background drugs. Since focus on only Akynzeo not on chemo drug, Akynzeo captured only primary drug. Please update further.
  • 14 Jul 2022 Planned End Date changed from 2 Feb 2022 to 2 Feb 2023.
  • 14 Jul 2022 Planned primary completion date changed from 2 Feb 2022 to 2 Feb 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top